UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Rey 1459

P O Box 1450 Alexandria, Virgima 22313-1450 www.uspto.gov

DATE MAILED: 03/20/2009

## NOTICE OF ALLOWANCE AND FEE(S) DUE

23373 7590 63/20/2009 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON DC 20037

EXAMINER					
MCINTOSH III, TRAVISS C					
ART UNIT	PAPER NUMBER				
1623	•				

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,895	09/19/2005	Hideki Fujikura	Q87150	6607
TITLE OF INVENTION: F	YRAZOLE DERIVATIVE.	MEDICINAL COMPOSITION CONTAINING THE SAME.	MEDICINAL USE THERE	EOF AND

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	06/22/2009

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 1SI. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

### HOW TO REPLY TO THIS NOTICE:

INTERMEDIATE IN PRODUCING THE SAME

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FFE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

### PART B - FEE(S) TRANSMITTAL

# Complete and send this form, together with applicable fee(s), to: Mail Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax (571)-273-2885

appropriate. All further indicated unless correcte maintenance fee notificat	correspondence includir d below or directed oth	or tran ig the l ierwise	Smitting the ISSU Patent, advance of in Block 1, by (a	ders and publication of r ders and notification of r specifying a new corres	naintenance fees w pondence address;	ill be and/or	mailed to the current (b) indicating a sepa	corresponde rate "FEE a	ence address as ADDRESS" for
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)			Not Fee pap	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.					
SUITE 800	VANIA AVENUE				Cer	tificate	of Mailing or Trans; s) Transmittal is being ficient postage for firs ISSUE FEE address 1) 273-2885, on the d	mission	
WASHINGTON	, DC 20037								(Depositor's name)
									(Signature)
									(Date)
APPLICATION NO.	FILING DATE			FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.		CONFIRM	IATION NO.
10/529,895	09/19/2005			Hideki Fujikura			Q87150	6	607
TITLE OF INVENTION INTERMEDIATE IN PR			, MEDICINAL CO	OMPOSITION CONTAIN	ING THE SAME,	MEDI	CINAL USE THERE	OF AND	
APPLN, TYPE	SMALL ENTITY	IS:	SUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUI	FEE	TOTAL FEE(S) DUE	DA	ATE DUE
nonprovisional	NO		\$1510	\$300	\$0		\$1810	06	/22/2009
EXAM	INER		ART UNIT	CLASS-SUBCLASS	]				
MCINTOSH II	I, TRAVISS C		1623	514-023000	•				
Change of correspondence address or indication of "Fee Address" (27 CFR 1.53).   Change of correspondence address for Change of Correspondence Address form PIOSB/122) altached.   Tee Address' findication for "Fee Address" indication form PIOSB/124 altached. Address' indication form PIOSB/142 altached. Address' indication form PIOSB/142 altached.   Address form Lee Address' indication form PIOSB/147 altached. Address for			Correspondence ation form e of a Customer	(1) the names of up to or agents OR, alternati (2) the name of a singl registered attorney or 2 registered patent atto listed, no name will be	2. For printing on the patient front page, list (1) the names of up 0.3 registered patient attorneys or agents OR, alternatively, (2) the name of a single firm (thaving as a member a registered attorney or agent) and the names of up to loved, no name will be printice, (2) registered patient attorneys or agents. If no name is  1 EVATENT (print or type)				
(A) NAME OF ASSIC	SNEE			data will appear on the p \( \text{T a substitute for filing an} \)  (B) RESIDENCE: (CITY  inted on the patent):	and STATE OR C	OUNT	'RY)		
4a. The following fee(s) a  ☐ Issue Fee ☐ Publication Fee (N ☐ Advance Order - #	o small entity discount p	ermitte		D. Payment of Fee(s): (Plea A check is enclosed. Payment by credit can The Director is hereby overpayment, to Depo	d. Form PTO-2038	is atta	ched.		
	SMALL ENTITY state	s. See	37 CFR 1.27.	☐ b. Applicant is no lon					
NOTE: The Issue Fee and interest as shown by the r	I Publication Fee (if req ecords of the United Sta	iired) v tes Pate	will not be accepted and Trademark	from anyone other than t Office.	he applicant; a regi	stered a	attorney or agent; or th	e assignee o	or other party in
Authorized Signature					Date				
Typed or printed name Registration No									
This collection of informan application. Confident submitting the completed this form and/or suggestit Box 1450, Alexandria, V Alexandria, Virginia 223	ation is required by 37 C iality is governed by 35 application form to the ons for reducing this bu- irginia 22313-1450. DC 13-1450.	FR 1.3 U.S.C. USPT den, st NOT	11. The informatic 122 and 37 CFR O. Time will vary nould be sent to th SEND FEES OR	on is required to obtain or in 1.14. This collection is est depending upon the indiversity of the complete of	retain a benefit by t imated to take 12 i idual case. Any co er, U.S. Patent and D THIS ADDRESS	he publ minutes mment Traden i. SENI	tic which is to file (and to complete, including s on the amount of tin nark Office, U.S. Depo D TO: Commissioner	by the USI g gathering, ne you requ artment of C for Patents,	TO to process), preparing, and ire to complete commerce, P.O. P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.



# UNITED STATES PATENT AND TRADEMARK OFFICE

### UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P O Box 1450 Alexandra, Virgima 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/529,895	09/19/2005	Hideki Fujikura	Q87150	6607	
23373 7	590 03/20/2009		EXAM	IINER	
SUGHRUE MION, PLLC		MCINTOSH III, TRAVISS C			
	ANIA AVENUE, N.W	•	ART UNIT	PAPER NUMBER	
SUITE 800 WASHINGTON, DC 20037		1623 DATE MAIL ED: 03/20/2009			

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 493 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 493 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

# Application No. Applicant(s) 10/529,895 FUJIKURA ET AL. Examiner Art Unit TRAVISS C. MCINTOSH III 1623 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address-All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed, a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOTA GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1,313 and MPEP 1308. 1. ☑ This communication is responsive to amendment filed 12/23/22008.

NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. This communication is responsive to amendment filed 12/23/2008. 2. The allowed claim(s) is/are 1-23. 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). b) ☐ Some\* c) ☐ None of the: a) X All 1. T Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. \_\_ 3. X Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). \* Certified copies not received: \_\_\_\_\_. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

U.S. Patent and Trademark Office PTOL 37 (Rev. 08-06)	Notice of Allowability	Part of Paner No /Mail Date 20090313
Paper No./Mail Date 1 <u>/2/23/08</u> 4.	8. 🛭 Examiner's Statem 9. 🗌 Other	ent of Reasons for Allowance
<ol> <li>Notice of Draftperson's Patent Drawing Review (PTO-9  3.   Information Disclosure Statements (PTO/SB/08),</li> </ol>	48) 6. ☐ Interview Summary Paper No./Mail Da 7. ☐ Examiner's Amend	ite
Attachment(s)  1. ☑ Notice of References Cited (PTO-892)	5. ☐ Notice of Informal F	Patent Application
<ol> <li>DEPOSIT OF and/or INFORMATION about the di attached Examiner's comment regarding REQUIREME</li> </ol>		

# REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: the prior art is not seen to teach or fairly suggest the pyrazole compounds instantly claimed. Specifically, the art does not teach the instantly claimed compounds which have the claimed saccharides in the 3- or 5-position of the pyrazole, the methyl linked cyclic groups in the 4-position, and the cyclic, alkoxy, amino, or heterocyclic groups in the non-saccharide 3- or 5-position. The closest art is seen to be US 6,815,428; US 6,972,283; US 7,084,123; US 7,087,579; and US 7,294,618, which all disclose various pyrazole compounds, but none which teach the cyclic, alkoxy, amino, or heterocyclic groups instantly claimed in the non-saccharide 3- or 5-position of the pyrazole (Q<sup>0</sup> or T<sup>0</sup> position of instant compounds), nor the intermediates instantly claimed. Likewise, Yamanouchi et al. (1996 – of record) discusses the role of the 1,5-anhydroglucitol/fructose/mannose transporters and the relationship with sodium/glucose transporting activity, thus showing the inhibition of 1,5-anhydroglucitol/fructose/mannose transporters provides efficacy in treating diseases associated with elevated glucose levels such as diabetes and diabetic complications.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

Art Unit: 1623

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Traviss C McIntosh III/ Primary Examiner, Art Unit 1623 March 14, 2009